Liver Neoplasm Clinical Trial
Official title:
Effectiveness of Routine Application Of Anterior Approach During Right Hepatectomy: A Randomized Trial
The aim of this study was to evaluated the advantages of routine application of the anterior approach in patients scheduled to right hepatectomy or extended right hepatectomy, without infiltration of segment 1, inferior vena cava or main bile duct.
Mobilization of the liver during right hepatectomy with classic approach is performed before parenchymal transection. In this phase severe bleeding may occur due to laceration of the inferior vena cava (IVC) wall, rupture or ligation falling off the hepatic short vein (HSV) or bleeding from the right liver attachments. Besides, the twisting of the portal pedicle during mobilization can render the left hepatic lobe ischemic for transient interruption of the hepatopetal flow. These events are more frequent in case of large hepatic lesions (mainly HCC) that involves surrounding structures (such as diaphragm). Two of the most important factors that affect the postoperative course of patients undergoing liver resections are indeed intraoperative bleeding and postoperative liver dysfunction. For these reasons Lai et al proposed anterior approach as alternative to classic right hepatectomy. In this case liver mobilization is performed only at the end of parenchymal transection, when all vascular connections are already interrupted. Liu et al published the results of a retrospective study in which 54 patients with, right sided HCC greater than 5 cm underwent right hepatectomy using the anterior approach technique. The anterior approach group had significantly less intraoperative blood loss, less need of blood transfusion and a lower hospital mortality rate. The same group reported results of a prospective randomized controlled study analyzing 120 patients with large (>5 cm) right liver HCC. The overall operative blood loss, morbidity, and duration of hospital stay were comparable in both groups. However, a higher number of patients in classic approach group experienced mayor operative blood loss (> 2000 cc) and required blood transfusions (8.3% vs. 28.3%). ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02557724 -
Mobilization of Mesenchymal Stem Cells During Liver Transplantation
|
||
Terminated |
NCT04702230 -
Value of Functional Magnetic Resonance Imaging of Hepatocellular Carcinoma After Transarterial Chemoembolization or Transarterial Radioembolization
|
||
Active, not recruiting |
NCT01217034 -
Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib
|
Phase 2 | |
Recruiting |
NCT05169177 -
Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy
|
||
Withdrawn |
NCT02599909 -
Gut Microbiota in People With Hepatocellular Carcinoma (HCC)
|
||
Terminated |
NCT03998033 -
Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma
|
Phase 1 | |
Recruiting |
NCT04010071 -
Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors
|
Phase 2 | |
Recruiting |
NCT04864054 -
T-Cell Therapy (ECT204) in Adults With Advanced HCC
|
Phase 2 | |
Terminated |
NCT04187937 -
Feasibility of Ultrasound-based Navigation for Non-anatomical Liver Resections
|
N/A | |
Completed |
NCT02471313 -
Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization
|
Phase 2 | |
Completed |
NCT00001576 -
A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver
|
Phase 1 | |
Recruiting |
NCT01542281 -
Pre-habilitation to Improve Outcomes in Patients Undergoing Liver Resection for Cancer
|
N/A | |
Recruiting |
NCT03803436 -
Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation
|
Phase 2 | |
Completed |
NCT05495529 -
Biliary or Digestive Protection by Room Air Interposition for Thermal Ablation of Central Hepatic Tumors
|
||
Recruiting |
NCT02632864 -
Feasibility of High Dose PROton Therapy On Unresectable Primary Carcinoma Of Liver: Prospective Phase II Trial
|
Phase 2 | |
Completed |
NCT02571946 -
Proton Beam Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
|
N/A | |
Withdrawn |
NCT00510627 -
Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases
|
Phase 4 | |
Completed |
NCT05848947 -
SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA
|
Phase 4 | |
Not yet recruiting |
NCT05723705 -
Impact of a European Training Program for Robotic Liver Surgery (LIVEROBOT)
|
||
Terminated |
NCT04502082 -
Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)
|
Phase 1/Phase 2 |